Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2004-06-04
2008-10-28
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Reexamination Certificate
active
07442761
ABSTRACT:
The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease.
REFERENCES:
patent: 5104854 (1992-04-01), Schlesinger et al.
patent: 5231167 (1993-07-01), Zanetti
patent: 5280113 (1994-01-01), Rademacher
patent: 5679352 (1997-10-01), Chong
patent: 5866690 (1999-02-01), Bogoch
patent: 6023659 (2000-02-01), Seilhamer
patent: 6070126 (2000-05-01), Kokolus
patent: 6242578 (2001-06-01), Bogoch
patent: 6256647 (2001-07-01), Toh
patent: 6470277 (2002-10-01), Chin
patent: 6484166 (2002-11-01), Maynard
patent: 6638505 (2003-10-01), Bogoch
patent: 7267942 (2007-09-01), Peiris et al.
patent: 2002/0120106 (2002-08-01), Bogoch et al.
patent: 2002/0151677 (2002-10-01), Bogoch et al.
patent: 2003/0180328 (2003-09-01), Bogoch
patent: 2003/0194414 (2003-10-01), Bogoch
patent: 2005/0271676 (2005-12-01), Sette et al.
patent: 0 108 564 (1984-05-01), None
patent: 98MI0874 (1999-10-01), None
patent: 96/32106 (1996-10-01), None
patent: WO 00/18351 (2000-04-01), None
patent: WO 01/04135 (2001-01-01), None
patent: 02085093 (2002-10-01), None
patent: 03005880 (2003-01-01), None
patent: 03/083058 (2003-10-01), None
Bogoch, S. et al., “A Checklist for Suitability of Biomarkers as Surrogate Endpoints in Chemoprevention of Breast Cancer,” Journal of Cellular Biochemistry, Supplement, Boston, US, vol. 19, pp. 173-185, XP009046492, ISSN: 0733-1959, 1994.
Marra, M. et al., “The Genome Sequence of the SARS-Associated Coronavirus,” Science, American Association For the Advancement of Science, US, v. 300, No. 5624, p. 1399-1404, XP002269483, ISSN: 0036-8075, May 30, 2003.
Qin, E. et al., “A Genome Sequence of Novel SARS-CoV Isolates: the Genotype, GD-Ins29, Leads to a Hypothesis of Viral Transmission in South China,” Genomics Proteomics & Bioinformatics, vol. 1, No. 2, p. 101-107, XP001206098, ISSN: 1672-0229, May 2003.
Rota, P. et al., “Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome,” Science, American Association for the Advancement of Science, US, v. 300, No. 5624, p. 1394-1399, XP002269482, ISSN: 0036-8075, May 30, 2003.
Tanaka, T. et al., “Efficient Generation of Antibodies to Oncoproteins by using Synthetic Peptide Antigens.”Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, D.C., US, v. 82, No. 10, p. 3400-3404, tables 1, Peptide 21, XP000113798, ISSN: 0027-8424, May 1, 1985.
Brumenu, T.D. et al., “Immunogenicity of a Contiguous T-B Synthetic Epitope of the A/PR/8/34 Influenza Virus,” Journal of Virology, Jul. 1997, vol. 71, No. 7, pp. 5473-5480.
Chambers, T.M. et al., “Antigenic and molecular characterization of subtype H13 hemagglutinin of influenza virus,” Database NCBI on STN, Accession No. HMIVT2, Virology, 1989, 172(1), pp. 180-188, abstract.
Gelder, C.M. et al. “Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection,” Journal of Virology, Dec. 1995, vol. 69, No. 12, pp. 7497-7506A.
O'Donnell, F.T. et al., “Epidemiology and molecular characterization of co-circulating influenza A/H3N2 virus variants in children,” Epidemiology and Infection, Jun. 2003, pp. 521-531, abstract, vol. 130, issue 3, The University of Texas-Houston School of Public Health, Houston, Texas.
PCT International Search Report, PCT/US2002/09240, Jan. 14, 2004, US Patent and Trademark Office, International Searching Authority, Washington, DC.
PCT International Search Report, PCT/US2002/21494, May 30, 2003, US Patent and Trademark Office, International Searching Authority, Washington, DC.
PCT International Preliminary Examination Report, PCT/US2002/21494, Nov. 26, 2004, US Patent and Trademark Office, International Preliminary Examining Authority, Washington, DC.
Brown, L. R. et al., “Recognition of the influenza hemagglutinin by Class II MHC-restricted T lymphocytes and antibodies,”Journal of ImmunologyOct. 15, 1991, pp. 2677-2684, vol. 147, No. 8, American Association of Immunologists, USA, XP02371257, ISSN: 0022-1767.
Atassi, M. Z. et al., “A novel approach for localization of the continuous protein antigenic sites by comprehensive synthetic surface scanning: Antibody and T cell activity to several influenza hemagglutinin synthetic sites,”Immunological Communications, 1984, pp. 539-551, vol. 13, No. 6, Marcel Dekker, Inc., XP009062995, ISSN: 0090-0877.
Carr, C. M. et al., “A spring-loaded mechanism for the conformational change of influenza hemagglutinin,”Cell, May 21, 1993, pp. 823-832, vol. 73, Cell Press, XP002059698, ISSN: 0092-8674.
Ben-Yedidia, T. et al., “Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection,”International Immunology, 1999, pp. 1043-1051, XP000914818, ISSN: 0953-8178.
Schenk, S. et al., “Four recombinant isoforms of Cor a 1, the major allergen of hazel pollen, show different reactivities with allergen-specific T-lymphocyte clones,”European Journal of Biochemistry, 1994, pp. 717-722, vol. 224, XP002371408, ISSN: 0014-2956.
Orlando, C. et al., “A monoclonal antibody directed against the catalytic site ofBacillus anthracisadenylyl cyclase identifies a novel mammalian brain catalytic subunit,”Biochemistry, 1992, pp. 3215-3222, vol. 31, American Chemical Society, XP002371438, ISSN: 0006-2960.
Bogoch, S, et al., “Rapid replication and Replikintm structures: basis of the AMASRTest and CAVAXR,” Cancer Detection and Prevention Online, Feb. 9, 2002, XP002350483.
Gao et al., Identification and characterization of T helper epitopes in the nucleoprotein of infuenza A virus, J Immunol. Nov. 1, 1989, vol. 143, No. 9, pp. 3007-3014, see Figure 1, first line, right hand side sequence (ERR . . . ), 3008, col. 1, Viruses and Other Ag and Immunization.
Shi et al., Immunogenicity and in vitro protective efficacy of a recombinant multistagePlasmodium falciparumcandidate vaccine. Proc. Nat'l. Acad. Sci., USA. Feb. 1999, vol. 96, No. 4, pp. 1615-1620, see Table 1 and p. 1616, Materials and Methods.
PCT International Preliminary Examination Report, PCT/US2002/09240, Feb. 5, 2004, USPTO, International Preliminary Examination Authority, Alexandria, VA, USA.
PCT Written Opinion of the International Searching Authority, PCT/US2004/017936, Apr. 7, 2005, EPO, International Searching Authority, Munich, DE.
PCT International Preliminary Report on Patentability, PCT/US2004/017936, Apr. 13, 2007, USPTO, International Preliminary Examinating Authority, Alexandria, VA, USA.
PCT Written Opinion of the International Searching Authority, PCT/US2005/014443, Apr. 12, 2006, EPO, International Searching Authority, Munich, DE.
PCT International Preliminary Report on Patentability, PCT/US2005/014443, Nov. 1, 2006, WIPO, International Bureau of WIPO, Geneva, Switzerland.
PCT International Search Report, PCT/US2006/05343, Sep. 25, 2007, USPTO, International Searching Authority, Alexandria, VA, USA.
Supplementary Partial European Search Report 99944002, Apr. 20, 2004, EPO, Munich, DE.
Supplementary Partial European Search Report 03721445.9, Dec. 12, 2006, EPO, International Searching Authority, Munich, DE.
NCBI accession # gi 75059 Jul. 16, 1999.
NCBI Listing JQ0032, residues 74-82, May 11, 2000.
NCBI Accession # AAK38298, Apr. 19, 2001.
Abrams M. B. et al., “Early Detection and Monitoring of cancer with the Anti-Malignin Antibody Test,” Cancer detection and Prevention, XX, XX, vol. 18, No. 1, 1994, pp. 65-78, XP000673180, ISSN:0361-090X.
Bogoch et al.: In vitro production of the general transformation antibody related to survival in human cancer patients; antimalignin antibody; Abstract, Cancer Detection and Prevention, 1988, vol. 12, Nos. 1-6, pp. 313-320. Database Medline on STN National Library of Medicine (Bethesda, MD, USA) No. 89025479.
Bogoch et al., “Aglyco Pathology of Viral Receptors in Dementias,&
Bogoch Elenore S.
Bogoch Samuel
Campell Bruce
Hill Myron G.
Kenyon & Kenyon LLP
LandOfFree
Replikin peptides and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Replikin peptides and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replikin peptides and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993995